Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Zura Bio","sponsor":"Zura Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$65.0 million","newsHeadline":"JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Zura Bio","sponsor":"JATT Acquisition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$4.2 million","newsHeadline":"Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"$80.0 million","newsHeadline":"Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Zura Bio

    Menu

    Zura Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Zura Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

              Details:

              The funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 (tibulizumab), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist, in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).

              Lead Product(s): Tibulizumab

              Therapeutic Area: Immunology Product Name: ZB-106

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Deep Track Capital

              Deal Size: $80.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement June 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Zura Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Disea...

              Details:

              Through the agreement, Zura Bio will expand its Immunology pipeline by including ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist.

              Lead Product(s): Tibulizumab

              Therapeutic Area: Immunology Product Name: ZB-106

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Eli Lilly

              Deal Size: Undisclosed Upfront Cash: $4.2 million

              Deal Type: Licensing Agreement April 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Zura Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Disea...

              Details:

              The net proceedings will be used to to initiate a Phase 2 study for ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist, in Systemic Sclerosis.

              Lead Product(s): Tibulizumab

              Therapeutic Area: Immunology Product Name: ZB-106

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Deep Track Capital

              Deal Size: $80.0 million Upfront Cash: $80.0 million

              Deal Type: Private Placement April 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Zura Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

              Details:

              The combined company will focus on the clinical development of pipeline candidates ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways.

              Lead Product(s): ZB-168

              Therapeutic Area: Endocrinology Product Name: ZB-168

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: JATT Acquisition

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger March 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Zura Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company

              Details:

              Proceeds from the transaction are expected to provide Zura Bio with the capital needed to accelerate the development of ZB-168, a fully-human, clinical-stage antibody targeting IL7Rα, that was recently in-licensed from Pfizer Inc.

              Lead Product(s): ZB-168

              Therapeutic Area: Endocrinology Product Name: ZB-168

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: JATT Acquisition Corp

              Deal Size: Undisclosed Upfront Cash: $65.0 million

              Deal Type: Merger June 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY